Advocacy intelligence hub — real-time data for patient organizations
First Affiliated Hospital of Wenzhou Medical University — PHASE4
Zhang Ting — EARLY_PHASE1
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Patient Assistance Programs1
Lynparza
AstraZeneca Pharmaceuticals LP
Sogroya
(somapacitan-beco)Orphan drugstandardNovo Nordisk Pharmaceuticals
12.1 Mechanism of Action Somapacitan-beco binds to a dimeric GH receptor in the cell membrane of target cells resulting in intracellular signal transd...
Rubraca
(rucaparib)Orphan drugstandardpharma&
12.1 Mechanism of Action Rucaparib is an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, including PARP-1, PARP-2, and PARP-3, which play a ...
Lynparza
(olaparib)Orphan drugstandardAstraZeneca Pharmaceuticals LP
Poly(ADP-Ribose) Polymerase Inhibitor [EPC]
12.1 Mechanism of Action Olaparib is an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, including PARP1, PARP2, and PARP3. PARP enzymes are ...
Browse all Idiopathic steroid-resistant nephrotic syndrome news →
View all Idiopathic steroid-resistant nephrotic syndrome specialists →